Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy

To overcome unsatisfactory results of classical low-dose cytarabine (LDAC) of cytarabine ≤20 mg twice daily (BID) subcutaneously for 10 days for patients with elderly acute myeloid leukemia (eAML), we evaluated a modified LDAC (mLDAC) of cytarabine 20 mg/m(2) BID subcutaneously plus etoposide 50 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Seung-Hwan, Cho, Byung-Sik, Park, Sung-Soo, Cho, Sung-Yeon, Jeon, Young-Woo, Yoon, Jae-Ho, Yahng, Seung-Ah, Lee, Sung-Eun, Lee, Dong-Gun, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung, Kim, Hee-Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814177/
https://www.ncbi.nlm.nih.gov/pubmed/29464037
http://dx.doi.org/10.18632/oncotarget.23629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814177/
https://www.ncbi.nlm.nih.gov/pubmed/29464037
http://dx.doi.org/10.18632/oncotarget.23629

Ejemplares similares